1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20


Publications since 2014

Kaplan, M., Narasimhan, S., de, H., Mance, D., van, D., Houben, K., Popov-Čeleketić, D., Damman, R., Katrukha, E., Jain, P., Geerts, W., Heck, A., Folkers, G., Kapitein, L., Lemeer, S., van, B. & Baldus, M. EGFR Dynamics Change during Activation in Native Membranes as Revealed by NMR. Cell (2016). [PubMed]
Weijer, R., Clavier, S., Zaal, E., Pijls, M., van, K., Vermaas, K., Leen, R., Jongejan, A., Moerland, P., van, K., van, K., Berkers, C., Lemeer, S. & Heger, M. Multi-OMIC profiling of survival and metabolic signaling networks in cells subjected to photodynamic therapy. Cell Mol Life Sci (2016). [PubMed]
Eichner, R., Heider, M., Fernández-Sáiz, V., van, B., Garz, A., Lemeer, S., Rudelius, M., Targosz, B., Jacobs, L., Knorn, A., Slawska, J., Platzbecker, U., Germing, U., Langer, C., Knop, S., Einsele, H., Peschel, C., Haass, C., Keller, U., Schmid, B., Götze, K., Kuster, B. & Bassermann, F. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nat Med 22, 735–43 (2016). [PubMed]
Schmidlin, T., Garrigues, L., Lane, C., Mulder, T., van, D., Post, H., de, G., Lemeer, S., Heck, A. & Altelaar, A. Assessment of SRM, MRM(3) , and DIA for the targeted analysis of phosphorylation dynamics in non-small cell lung cancer. Proteomics 16, 2193–205 (2016). [PubMed]
Ruprecht, B., Roesli, C., Lemeer, S. & Kuster, B. MALDI-TOF and nESI Orbitrap MS/MS identify orthogonal parts of the phosphoproteome. Proteomics 16, 1447–56 (2016). [PubMed]
Ruprecht, B., Zecha, J., Heinzlmeir, S., Médard, G., Lemeer, S. & Kuster, B. Evaluation of Kinase Activity Profiling Using Chemical Proteomics. ACS Chem Biol 10, 2743–52 (2015). [PubMed]
Baumann, U., Fernández-Sáiz, V., Rudelius, M., Lemeer, S., Rad, R., Knorn, A., Slawska, J., Engel, K., Jeremias, I., Li, Z., Tomiatti, V., Illert, A., Targosz, B., Braun, M., Perner, S., Leitges, M., Klapper, W., Dreyling, M., Miething, C., Lenz, G., Rosenwald, A., Peschel, C., Keller, U., Kuster, B. & Bassermann, F. Disruption of the PRKCD-FBXO25-HAX-1 axis attenuates the apoptotic response and drives lymphomagenesis. Nat Med 20, 1401–9 (2014). [PubMed]
Ruprecht, B., Koch, H., Medard, G., Mundt, M., Kuster, B. & Lemeer, S. Comprehensive and reproducible phosphopeptide enrichment using iron immobilized metal ion affinity chromatography (Fe-IMAC) columns. Mol Cell Proteomics 14, 205–15 (2015). [PubMed]
Lemeer, S., Gholami, A., Wu, Z. & Kuster, B. Quantitative proteome profiling of human myoma and myometrium tissue reveals kinase expression signatures with potential for therapeutic intervention. Proteomics 15, 356–64 (2015). [PubMed]
Helm, D., Vissers, J., Hughes, C., Hahne, H., Ruprecht, B., Pachl, F., Grzyb, A., Richardson, K., Wildgoose, J., Maier, S., Marx, H., Wilhelm, M., Becher, I., Lemeer, S., Bantscheff, M., Langridge, J. & Kuster, B. Ion mobility tandem mass spectrometry enhances performance of bottom-up proteomics. Mol Cell Proteomics 13, 3709–15 (2014). [PubMed]
Wilhelm, M., Schlegl, J., Hahne, H., Gholami, A., Lieberenz, M., Savitski, M., Ziegler, E., Butzmann, L., Gessulat, S., Marx, H., Mathieson, T., Lemeer, S., Schnatbaum, K., Reimer, U., Wenschuh, H., Mollenhauer, M., Slotta-Huspenina, J., Boese, J., Bantscheff, M., Gerstmair, A., Faerber, F. & Kuster, B. Mass-spectrometry-based draft of the human proteome. Nature 509, 582–7 (2014). [PubMed]
Ruprecht, B. & Lemeer, S. Proteomic analysis of phosphorylation in cancer. Expert Rev Proteomics 11, 259–67 (2014). [PubMed]
Neumann, K., Castiñeiras-Vilariño, M., Höckendorf, U., Hannesschläger, N., Lemeer, S., Kupka, D., Meyermann, S., Lech, M., Anders, H., Kuster, B., Busch, D., Gewies, A., Naumann, R., Groß, O. & Ruland, J. Clec12a is an inhibitory receptor for uric acid crystals that regulates inflammation in response to cell death. Immunity 40, 389–99 (2014). [PubMed]
Hahne, H., Pachl, F., Ruprecht, B., Maier, S., Klaeger, S., Helm, D., Médard, G., Wilm, M., Lemeer, S. & Kuster, B. DMSO enhances electrospray response, boosting sensitivity of proteomic experiments. Nat Methods 10, 989–91 (2013). [PubMed]
Pachl, F., Ruprecht, B., Lemeer, S. & Kuster, B. Characterization of a high field Orbitrap mass spectrometer for proteome analysis. Proteomics 13, 2552–62 (2013). [PubMed]
Marx, H., Lemeer, S., Schliep, J., Matheron, L., Mohammed, S., Cox, J., Mann, M., Heck, A. & Kuster, B. A large synthetic peptide and phosphopeptide reference library for mass spectrometry-based proteomics. Nat Biotechnol 31, 557–64 (2013). [PubMed]
Marx, H., Lemeer, S., Klaeger, S., Rattei, T. & Kuster, B. MScDB: a mass spectrometry-centric protein sequence database for proteomics. J Proteome Res 12, 2386–98 (2013). [PubMed]
Lemeer, S., Zörgiebel, C., Ruprecht, B., Kohl, K. & Kuster, B. Comparing immobilized kinase inhibitors and covalent ATP probes for proteomic profiling of kinase expression and drug selectivity. J Proteome Res 12, 1723–31 (2013). [PubMed]
Fernández-Sáiz, V., Targosz, B., Lemeer, S., Eichner, R., Langer, C., Bullinger, L., Reiter, C., Slotta-Huspenina, J., Schroeder, S., Knorn, A., Kurutz, J., Peschel, C., Pagano, M., Kuster, B. & Bassermann, F. SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma. Nat Cell Biol 15, 72–81 (2013). [PubMed]
Bantscheff, M., Lemeer, S., Savitski, M. & Kuster, B. Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present. Anal Bioanal Chem 404, 939–65 (2012). [PubMed]